Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25020784 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Serena Ammendola und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology, Department of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata of Verona, 37134 Verona, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Cryoglobulinemia, Hepatitis C, Cholestasis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Verona.
Abstract (Originalsprache)
Twenty-nine patients with HCV infection (HCV+) and mixed cryoglobulinemia (MC+) were retrospectively selected and matched for age and sex with 31 HCV+ MC− patients. Biomarkers of cholestasis (direct bilirubin, alkaline phosphatase, and gamma-glutamyl transferase), HCV-RNA and genotype, and plasma cryoprecipitates were measured before and after virus eradication; liver histology and plasma cells (aggregation and distribution), observed blinded by two pathologists, were analyzed. Sixty participants (mean age: 56.5; range: 35–77, males: 50%) with HCV infection were enrolled. Cholestasis (≥2 pathologically increased cholestasis biomarkers) was significantly higher in the MC group (p = 0.02) and correlated with cryoglobulinemia (OR 6.52; p = 0.02). At liver histological assessment, plasma cells were significantly increased in the MC+ group (p = 0.004) and tended to form aggregates more than the control group (p = 0.05). At multivariate analysis with MC, age, HCV-RNA, HBV diabetes, and cirrhosis, cholestasis was only significantly correlated to MC (OR 8.30; p < 0.05). In 25% patients, MC persisted after virus eradication with new antiviral treatment. Our study identified for the first time an association between MC, cholestasis, and an increased number of intrahepatic plasma cells in chronic hepatitis C (CHC) patients before virus eradication. Future studies are required to understand how MC contributes to liver damage and how its persistence affects the patients’ follow-up after antiviral therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pathology, Department of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata of Verona, 37134 Verona, Italy.
- Division of General Medicine C, Department of Medicine, Azienda Ospedaliera Universitaria Integrata of Verona, 37134 Verona, Italy.
- Liver Unit, Department of Medicine, University of Verona, 37129 Verona, Italy.
- Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37129 Verona, Italy.
ORCID-Profile: Serena Ammendola, Anna Mantovani, Martina Montagnana, Andrea Dalbeni
Förderung
- University of Verona
Zitieren
APA
Ammendola, S., Romeo, S., Cattazzo, F., Mantovani, A., Ieluzzi, D., Paon, V., Montagnana, M., Pecori, S., Tomezzoli, A., Dalbeni, A., & Sacerdoti, D. (2024). Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25020784
Vancouver
Ammendola S, Romeo S, Cattazzo F, Mantovani A, Ieluzzi D, Paon V, et al. Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25020784
BibTeX
@article{Ammendola2024,
author = {Ammendola, Serena and Romeo, Sara and Cattazzo, Filippo and Mantovani, Anna and Ieluzzi, Donatella and Paon, Veronica and Montagnana, Martina and Pecori, Sara and Tomezzoli, Anna and Dalbeni, Andrea and Sacerdoti, David},
title = {Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies—A Case-Control Study},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25020784}
}
EUVIMED